Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

58.67 -2.23 (-3.66%)

Streaming Delayed Price Updated: 11:45 AM EDT, Aug 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

36 37 Next >

Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit? ↗

June 21, 2023

There's more than one reason to sell a stock while buying another.

Via The Motley Fool

Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030 ↗

June 21, 2023

This company has several catalysts for growth coming up, with more on the way.

Via The Motley Fool

Is CRISPR Therapeutics Stock a Buy Now? ↗

June 21, 2023

CRISPR stock has climbed more than 40% so far this year.

Via The Motley Fool

3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever ↗

June 20, 2023

Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires.

Via InvestorPlace

Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy ↗

June 18, 2023

Success could be in the DNA of the Ark Invest founder.

Via The Motley Fool

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

Where Will CRISPR Therapeutics Be in 10 Years? ↗

June 14, 2023

The biotech is part of a revolution in gene-editing therapies.

Via The Motley Fool

What 17 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

June 09, 2023

Via Benzinga

3 Cathie Wood Investments That Could Deliver Superior Returns ↗

June 17, 2023

These three stocks fit Wood's profile for big-time growth.

Via The Motley Fool

2 Short-Squeeze Candidates That Could Go Parabolic ↗

June 15, 2023

Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.

Via The Motley Fool

This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics? ↗

June 13, 2023

All eyes are on CRISPR Therapeutics' gene editing technology.

Via The Motley Fool

5 Stocks to Buy With Explosive 500% Potential ↗

June 12, 2023

Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential.

Via InvestorPlace

2 Biotech Stocks That Could Help Make You a Fortune ↗

June 12, 2023

Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time.

Via The Motley Fool

Can This Gene-Editing Stock Deliver 10X Returns? ↗

June 08, 2023

Buying shares of Intellia Therapeutics might be a smart move.

Via The Motley Fool

CRISPR Therapeutics: A Galaxy's Worth of Deep Value ↗

May 31, 2023

Wall Street is at max pessimism with this biotech, which might be a big mistake.

Via The Motley Fool

3 Disruptors I Love Right Now ↗

May 30, 2023

These stocks could deliver huge returns as the companies transform the economy.

Via The Motley Fool

3 No-Brainer Stocks to Buy in June ↗

June 10, 2023

These biopharma stocks could be big winners.

Via The Motley Fool

Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application ↗

June 09, 2023

The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent

Via Benzinga

Vertex/CRISPR Partnered Cell Therapy Shows Encouraging In Sickle Cell Disease, Thalassemia Patients ↗

June 09, 2023

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent...

Via Benzinga

Carvana (CVNA) Stock Continues to Move on Improved Outlook ↗

June 09, 2023

Carvana (CVNA) stock is still a hot topic among traders on Friday after the used-car retailer updated its outlook yesterday.

Via InvestorPlace

TGT Stock Alert: Have Target’s Sales Numbers Peaked? ↗

June 09, 2023

Target (TGT) stock is in hot water on Friday after Citi analyst Paul Lejuez warned investors to stay away from the retailer.

Via InvestorPlace

Why Is CRISPR Therapeutics (CRSP) Stock Moving Today? ↗

June 09, 2023

CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials.

Via InvestorPlace

Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months ↗

June 09, 2023

The agency said it will make an approval decision on Crispr's exa-cel in December.

Via Investor's Business Daily

Wall Street Loves These 3 Growth Stocks -- Should You? ↗

June 09, 2023

Analysts think all three of these stocks could soar.

Via The Motley Fool

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

June 09, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

June 08, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

June 08, 2023

Today, CRISPR has reached an important turning point.

Via The Motley Fool

Cathie Wood Is Buying the SEC Lawsuit Dip in Coinbase (COIN) Stock ↗

June 07, 2023

Coinbase and the crypto industry at large is at war with regulators. But Cathie Wood is still buying shares of COIN stock.

Via InvestorPlace

Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today? ↗

June 06, 2023

Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector.

Via InvestorPlace

3 Top Healthcare Stocks to Buy for June ↗

June 06, 2023

These stocks have what it takes to deliver long-term growth.

Via The Motley Fool

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.